Sahkar Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.50 M
as on 09-12-2024
- Revenue 41.62%
(FY 2015)
- Profit -2.65%
(FY 2015)
- Ebitda 11.26%
(FY 2015)
- Net Worth 3.37%
(FY 2015)
- Total Assets 6.91%
(FY 2015)
About Sahkar Pharmaceuticals
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹5.50 M.
Geetaben Buha and Mukeshbhai Buha serve as directors at the Company.
- CIN/LLPIN
U24230GJ2005PTC045620
- Company No.
045620
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Mar 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sahkar Pharmaceuticals Private Limited offer?
Sahkar Pharmaceuticals Private Limited offers a wide range of products and services, including Fertilizers and Soil Additives, Nitrogen Fertilizers, Fertilizer, Plant Growth Promoters, Pharma Ingredients & Raw Materials, Anti Infective API, Industrial Chemicals & Supplies, Liquid Phenol, Organic Fertilizers and Manure, Micronutrient Fertilizers.
Who are the key members and board of directors at Sahkar Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Geetaben Buha  | Director | 04-Mar-2005 | Current |
| Mukeshbhai Buha | Director | 04-Mar-2005 | Current |
Financial Performance of Sahkar Pharmaceuticals.
Sahkar Pharmaceuticals Private Limited, for the financial year ended 2015, experienced significant growth in revenue, with a 41.62% increase. The company also saw a slight decrease in profitability, with a 2.65% decrease in profit. The company's net worth moved up by a moderate rise of 3.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sahkar Pharmaceuticals?
In 2017, Sahkar Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 11 Aug 2008 | ₹1.50 M | Open |
The United Western Bank Limited Creation Date: 11 Mar 2005 | ₹1.50 M | Open |
The United Western Bank Limited Creation Date: 10 Mar 2005 | ₹2.50 M | Open |
How Many Employees Work at Sahkar Pharmaceuticals?
Unlock and access historical data on people associated with Sahkar Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sahkar Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sahkar Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
